Cytokinetics, Incorporated (CYTK) Stock Analysis & AI Equity Report
Cytokinetics, Incorporated (CYTK) overview
Cytokinetics, Incorporated (CYTK) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 88.0m and operating profit of USD -612m; the year-end share price was 63.54 USD and market capitalisation was USD 7,812m. Cytokinetics, Incorporated is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Cytokinetics, Incorporated's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About Cytokinetics, Incorporated
Cytokinetics discovers, develops and commercializes medicines that modulate muscle function for diseases involving impaired muscle performance. Its first commercial product, MYQORZO (aficamten), is a tablet approved for adults with obstructive hypertrophic cardiomyopathy. The company’s research focuses on muscle biology and includes investigational small-molecule candidates at discovery, preclinical and clinical stages. Its medicines and development programs address cardiovascular and neuromuscular diseases.
Generate the Cytokinetics, Incorporated report
Cytokinetics, Incorporated is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Cytokinetics, Incorporated and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Cytokinetics, Incorporated
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.